---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-009063"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:39:14.940475+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Reviva Pharmaceuticals announces $10M public offering of stock and warrants

## Summary
- Offering of 6,666,667 shares (or pre-funded warrants) plus Series G and H warrants at $1.50/unit; gross proceeds $10M.
- Series G warrants exercisable at $1.50 for 5 years; Series H warrants exercisable at $1.50 for 1 year.
- Net proceeds ~$9M to fund RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia and for working capital.
- Closing expected March 20, 2026; A.G.P./Alliance Global Partners acting as sole placement agent.

## SEC filing metadata
- accession: 0001437749-26-009063
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774926009063/0001437749-26-009063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774926009063/rvph20260319_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-009063
- JSON: https://secwatch.observer/filing/0001437749-26-009063.json
- Plain text: https://secwatch.observer/filing/0001437749-26-009063.txt

## Key facts
- Material Agreements
  REVIVA PHARMACEUTICALS HOLDINGS, INC. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at 7.0% of the aggregate gross proceeds (effective 2026-03-18).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: A.G.P./Alliance Global Partners
  - Value: 7.0% of the aggregate gross proceeds
  - Effective: 2026-03-18
  source text: the Company entered into a placement agency agreement (the “Placement Agency Agreement”), dated March 18, 2026, with A.G.P./Alliance Global Partners (the “Placement Agent”) pursuant to which the Company agreed to pay the Placement Agent a total cash fee equal to 7.0% of the aggregate gross proceeds of the Offering
  evidence_url: https://www.sec.gov/Archives/edgar/data/1742927/000143774926009063/0001437749-26-009063-index.htm
- Material Agreements
  REVIVA PHARMACEUTICALS HOLDINGS, INC. entered into Purchase Agreement with certain institutional investors valued at $10.0 million (effective 2026-03-18).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Value: $10.0 million
  - Effective: 2026-03-18
  source text: On March 18, 2026, Reviva Pharmaceuticals Holdings, Inc. (the “Company”) entered into agreements, including a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to sell and issue, in a registered public offering (the “Offering”), (i) an aggregate of 6,283,334 shares (the “Shares”) of the Company’s common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1742927/000143774926009063/0001437749-26-009063-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.